Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Apollo Medical Holdings, Inc. | tv500936_8k.htm |
Exhibit 99.1
APOLLO MEDICAL HOLDINGS REPORTS 51% REVENUE INCREASE YEAR OVER YEAR FOR THE 2ND QUARTER OF 2018
Alhambra, CA and Glendale, CA – (PR Newswire) – August 14, 2018 – Apollo Medical Holdings, Inc. (“ApolloMed” or “the Company”) (NASDAQ: AMEH), an integrated population health management company, today announced its consolidated 2nd Quarter financial results for the three and six months ended June 30, 2018.
Financial Highlights for the Three Months Ended June 30, 2018 Compared to the Three Months Ended June 30, 2017 (unaudited):
| § | Net revenue of $123.0 million for the three months ended June 30, 2018 as compared to net revenue of $81.3 million in the comparable period of 2017, an increase of 51%. |
| § | Income from operations of $7.1 million for the three months ended June 30, 2018 as compared to $4.1 million in the comparable period of 2017, an increase of 76%. |
| § | Net income attributable to Apollo Medical Holdings, Inc. of $2.7 million for the three months ended June 30, 2018 as compared to $2.0 million in the comparable period of 2017, an increase of 34%. |
| § | As of June 30, 2018, the Company had total assets of $511.0 million, including cash and cash equivalents of $101.1 million. |
Recent Highlights:
| § | On June 25, 2018, the Company announced that it had been added to the Russell 3000© Index and the Russell Microcap Index©. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s US indexes. |
| § | In June 2018, the Company’s subsidiary, Network Medical Management, Inc. (“NMM”) and its consolidated variable interest entity, Allied Pacific of California, partnered with College Street Investment LP, a California limited partnership, to acquire the recently closed 128-bed French Hospital in Downtown Los Angeles, California, for approximately $33.3 million for the benefit of 531 W. College, LLC. The plan is to convert the 2.5 acre, 90,000-square foot facility into an integrated care center, complete with a 24-hour urgent care center, multispecialty clinics, imaging center, diagnostic lab, pharmacy, behavioral care center and infusion center. |
“We are pleased to announce our 2nd quarter results for 2018 which reflect the increases that resulted from our merger with NMM and demonstrate continued momentum from the start of the year and our unrelenting focus on operational excellence,” stated Eric Chin, Chief Financial Officer of ApolloMed. “Highlights of this quarter include total revenue increase of 51% year-over-year, net income increase of 34% year-over-year and quarterly net income increase of 23% over net income in our 1st quarter of 2018. The year-over-year revenue increase reflects the results of the post-merger companies and was driven by an increase in patients under capitation.”
“Our team delivered another strong quarter with year-over-year increase in both revenue and net income, driven by solid execution of our strategic plan,” stated Warren Hosseinion, M.D., Co-Chief Executive Officer of ApolloMed. “We are committed to the continued growth of our company and to creating long-term value for our shareholders.”
“We believe that our merger integration is near completion and that we are now well positioned for the future,” stated Thomas Lam, M.D., Co-Chief Executive Officer of ApolloMed. “The long-term demand drivers in our industry are solid, including the shift to value-based reimbursements and an aging population.”
“We have demonstrated a commitment to and leadership in population health management,” stated Kenneth Sim, M.D., Executive Chairman of ApolloMed. “We would like to thank each of our employees, physicians, hospital partners and other providers for their dedication and hard work, which continues to be the catalyst for our long-term success.”
For more details on ApolloMed’s June 30, 2018 quarter end results, please refer to the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities Exchange Commission (“SEC”) and accessible at www.sec.gov.
APOLLO MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| June 30, 2018 | December 31, 2017 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 101,132,237 | $ | 99,749,199 | ||||
| Restricted cash – short-term | 8,040,870 | 18,005,661 | ||||||
| Fiduciary cash | 1,294,503 | 2,017,437 | ||||||
| Investment in marketable securities | 1,130,967 | 1,143,095 | ||||||
| Receivables, net | 34,541,815 | 20,117,304 | ||||||
| Prepaid expenses and other current assets | 6,622,549 | 3,126,866 | ||||||
| Total current assets | 152,762,941 | 144,159,562 | ||||||
| Noncurrent assets | ||||||||
| Land, property and equipment, net | 13,297,168 | 13,814,306 | ||||||
| Intangible assets, net | 94,927,036 | 103,533,558 | ||||||
| Goodwill | 189,604,746 | 189,847,202 | ||||||
| Loans receivable – related parties | 7,500,000 | 5,000,000 | ||||||
| Loan receivable | 10,000,000 | 10,000,000 | ||||||
| Investment in a privately held entity that does not report net asset value per share | 405,000 | - | ||||||
| Investments in other entities – equity method | 23,545,361 | 21,903,524 | ||||||
| Investment in joint venture – equity method | 16,673,840 | - | ||||||
| Restricted cash – long-term | 745,352 | 745,235 | ||||||
| Other assets | 1,515,664 | 1,632,406 | ||||||
| Total noncurrent assets | 358,214,167 | 346,476,231 | ||||||
| Total assets | $ | 510,977,108 | $ | 490,635,793 | ||||
APOLLO MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)
(UNAUDITED)
| June 30, 2018 | December 31, 2017 | |||||||
| Liabilities, Mezzanine Equity and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Lines of credit, short-term | $ | - | $ | 5,025,000 | ||||
| Accounts payable and accrued expenses | 12,587,893 | 13,279,620 | ||||||
| Incentives payable | 5,104,074 | 21,500,000 | ||||||
| Fiduciary accounts payable | 1,294,503 | 2,017,437 | ||||||
| Medical liabilities | 66,853,335 | 63,972,318 | ||||||
| Income taxes payable | 2,900,056 | 3,198,495 | ||||||
| Bank loan, short-term | 278,017 | 510,391 | ||||||
| Capital lease obligations | 100,228 | 98,738 | ||||||
| Total current liabilities | 89,118,106 | 109,601,999 | ||||||
| Noncurrent liabilities | ||||||||
| Lines of credit, long-term | 13,000,000 | - | ||||||
| Deferred tax liability | 27,758,780 | 24,916,598 | ||||||
| Liability for unissued equity shares | 1,185,025 | 1,185,025 | ||||||
| Dividends payable | 8,617,210 | 18,000,000 | ||||||
| Capital lease obligations, net of current portion | 568,512 | 619,001 | ||||||
| Total noncurrent liabilities | 51,129,527 | 44,720,624 | ||||||
| Total liabilities | 140,247,633 | 154,322,623 | ||||||
| Commitments and Contingencies | ||||||||
| Mezzanine equity | ||||||||
| Noncontrolling interest in Allied Pacific of California | 195,914,319 | 172,129,744 | ||||||
| Stockholders’ equity | ||||||||
| Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding | - | - | ||||||
| Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding | - | - | ||||||
| Common stock, par value $0.001; 100,000,000 shares authorized, 32,841,170 and 32,304,876 shares outstanding, excluding 1,682,110 treasury shares held by APC, at June 30, 2018 and December 31, 2017, respectively | 32,841 | 32,305 | ||||||
| Additional paid-in capital | 162,027,547 | 158,181,192 | ||||||
| Retained earnings | 7,561,556 | 1,734,531 | ||||||
| 169,621,944 | 159,948,028 | |||||||
| Noncontrolling interest | 5,193,212 | 4,235,398 | ||||||
| Total stockholders’ equity | 174,815,156 | 164,183,426 | ||||||
| Total liabilities, mezzanine equity and stockholders’ equity | $ | 510,977,108 | $ | 490,635,793 | ||||
APOLLO MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenue | ||||||||||||||||
| Capitation, net | $ | 90,316,182 | $ | 62,879,587 | $ | 176,221,466 | $ | 127,595,720 | ||||||||
| Risk pool settlements and incentives | 13,866,217 | 8,358,598 | 31,852,953 | 19,495,798 | ||||||||||||
| Management fee income | 12,371,608 | 6,287,702 | 24,446,180 | 12,824,812 | ||||||||||||
| Fee-for-service, net | 5,679,469 | 3,044,548 | 13,427,578 | 5,708,461 | ||||||||||||
| Other income | 771,070 | 741,265 | 1,223,096 | 1,022,971 | ||||||||||||
| Total revenue | 123,004,546 | 81,311,700 | 247,171,273 | 166,647,762 | ||||||||||||
| Expenses | ||||||||||||||||
| Cost of services | 99,464,892 | 66,672,236 | 184,135,500 | 126,214,808 | ||||||||||||
| General and administrative expenses | 11,471,829 | 5,777,187 | 23,207,727 | 11,053,762 | ||||||||||||
| Depreciation and amortization | 4,918,078 | 4,805,979 | 9,976,590 | 9,642,330 | ||||||||||||
| Total expenses | 115,854,799 | 77,255,402 | 217,319,817 | 146,910,900 | ||||||||||||
| Income from operations | 7,149,747 | 4,056,298 | 29,851,456 | 19,736,862 | ||||||||||||
| Other income (expense) | ||||||||||||||||
| Income (loss) from equity method investments | 1,669,861 | (795,102 | ) | 1,641,837 | 1,432,160 | |||||||||||
| Interest expense | (110,683 | ) | (575 | ) | (195,684 | ) | (1,386 | ) | ||||||||
| Interest income | 339,816 | 209,492 | 609,634 | 391,777 | ||||||||||||
| Change in fair value of derivative instruments | - | (1,394,443 | ) | - | 127,779 | |||||||||||
| Other income | 340,659 | 26,624 | 428,652 | 28,138 | ||||||||||||
| Total other income (expense), net | 2,239,653 | (1,954,004 | ) | 2,484,439 | 1,978,468 | |||||||||||
| Income before provision for income taxes | 9,389,400 | 2,102,294 | 32,335,895 | 21,715,330 | ||||||||||||
| Provision for income taxes | 1,523,807 | 736,835 | 8,752,647 | 8,626,080 | ||||||||||||
| Net income | 7,865,593 | 1,365,459 | 23,583,248 | 13,089,250 | ||||||||||||
| Net income (loss) attributable to noncontrolling interest | 5,201,491 | (629,284 | ) | 18,758,691 | 6,744,846 | |||||||||||
| Net income attributable to Apollo Medical Holdings, Inc. | $ | 2,664,102 | $ | 1,994,743 | $ | 4,824,577 | $ | 6,344,404 | ||||||||
| Earnings per share – basic | $ | 0.08 | $ | 0.08 | $ | 0.15 | $ | 0.25 | ||||||||
| Earnings per share – diluted | $ | 0.07 | $ | 0.07 | $ | 0.13 | $ | 0.22 | ||||||||
| Weighted average shares of common stock outstanding – basic | 32,674,459 | 25,067,954 | 32,548,662 | 25,067,954 | ||||||||||||
| Weighted average shares of common stock outstanding – diluted | 37,850,679 | 28,417,877 | 37,935,773 | 28,417,877 | ||||||||||||
Note About Historical Results for Periods Prior to the Merger
Following the closing of the merger involving ApolloMed and NMM in December 2017 (the “Merger”), NMM is now a wholly-owned subsidiary of ApolloMed. Although ApolloMed was the legal acquirer in the Merger, for accounting purposes, the Merger is treated as a “reverse acquisition,” and NMM is considered the accounting acquirer and ApolloMed is the accounting acquiree. Accordingly, the condensed consolidated financial statements included above and the description of the Company’s results of operations for the three and six month periods in 2017 reflect the operations of NMM and its consolidated variable interest entities (“VIEs”) during those periods, and the condensed consolidated financial statements and the description of the Company’s results of operations for the three and six month periods in 2018 reflect the combined operations of ApolloMed and NMM and its consolidated VIEs. Because the financial results for the reported periods in 2017 exclude the results of ApolloMed, the foregoing results of operations in 2018 are not directly comparable to the Company’s results of operations in the 2017 periods.
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company’s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the Company’s condensed consolidated statements of income.
Note About Stockholders’ Equity, Certain Treasury Stock and Earnings Per Share
As of the date of this press release, 751,067 shares of ApolloMed’s common stock to be issued as part of the Merger are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The Company’s condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares as of the closing of the Merger.
Shares of ApolloMed’s common stock owned by Allied Physicians of California IPA (d.b.a. Allied Pacific of California IPA), a variable interest entity of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company’s condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company’s earnings per share.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization (“NGACO”), and its affiliated independent practice associations (“IPAs”) and management services organizations (“MSOs”), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner. Led by a management team with over two decades of experience, ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes NMM (MSO), Apollo Medical Management (MSO), ApolloMed Hospitalists, APA ACO (NGACO), Allied Physicians of California (IPA) and Apollo Care Connect (Digital Population Health Management Platform). ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company’s operational focus, strategic growth plans, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K filed with the SEC on April 2, 2018.
For More Information, PLEASE CONTACT:
Warren
Hosseinion, M.D.
Co-Chief Executive
Officer
Apollo Medical
Holdings, Inc.
(818) 839-5200
warrenhoss@apollomed.net